(Q48235785)

30 June 2019

title

Acquired resistance to immunotherapy and future challenges. (English)

1 reference

30 June 2019

1 reference

2

1 reference

http://europepmc.org/abstract/MED/26822578

9 February 2018

Nicholas P. Restifo

object named as

Nicholas P Restifo

series ordinal

1

0 references

author name string

Alexandra Snyder

series ordinal

3

1 reference

30 June 2019

language of work or name

English

0 references

publication date

1 February 2016

1 reference

30 June 2019

published in

Nature Reviews Cancer

1 reference

30 June 2019

volume

16

1 reference

30 June 2019

issue

2

1 reference

30 June 2019

page(s)

121-126

1 reference

30 June 2019

https://scigraph.springernature.com/pub.10.1038/nrc.2016.2

exact match

0 references

cites work

Adoptive immunotherapy for cancer: harnessing the T cell response

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Cancer and the Immune System: Basic Concepts and Targets for Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

MHC ligands and peptide motifs: first listing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Adoptive cell transfer as personalized immunotherapy for human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Cancer immunoediting by the innate immune system in the absence of adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Adaptive immunity maintains occult cancer in an equilibrium state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Expression of tumour-specific antigens underlies cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Molecular and genetic properties of tumors associated with local immune cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Neoantigens in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

T cell exclusion, immune privilege, and the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Paths to stemness: building the ultimate antitumour T cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Prospects for gene-engineered T cell immunotherapy for solid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Genetics and immunology: reinvigorated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

CANCER. The odds of immunotherapy success

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Classifying Cancers Based on T-cell Infiltration and PD-L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Genetic basis for clinical response to CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Can money really be no object when cancer care is the subject?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.2

Genetic basis for clinical response to CTLA-4 blockade

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26822578

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

On immunosurveillance in human cancer.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26822578

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRC.2016.2

1 reference

30 June 2019

PMCID

6330026

1 reference

30 June 2019

PubMed ID

26822578

1 reference

30 June 2019